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Hepatitis C virus (HCV), an important human pathogen, is an enveloped, positive-stranded RNAvirus classified in the hepacivirus genus of the
Flaviviridae family. Cell attachment of flaviviruses generally leads to endocytosis of bound virions. Systems that support HCV replication and
particle formation in vitro are emerging only now, 16 years after the discovery of the virus. Albeit this limitation, the route of HCV cell entry as
well as ‘capture’ molecules involved in low-affinity interactions for the initial contact of HCV with target cells and potential high-affinity receptor
candidates that may mediate HCV trafficking and fusion has been described. The objective of this review is to summarize the contribution of
different HCV model systems to our current knowledge about structure of the HCV GPs E1 and E2 and their roles in cell entry comprising cell
attachment, interactions with cellular receptors, endocytosis, and fusion.
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Hepatitis C virus (HCV) infection leads in 50 to 80% of
cases to chronic hepatitis, liver cirrhosis, and hepatocellular
carcinoma. Interferons and the nucleoside analogue ribavirin
form the basis for treatment, but are not sufficiently effective
and have numerous side effects. While about 200 million people
worldwide are estimated to be infected, the characterization of
HCV biology and associated pathologies and development of
new therapeutics have been slow. Systems that support HCV
replication and particle formation in vitro are only emerging
now, 16 years after the discovery of the virus, and infection
models have remained limited to chimpanzee (Lanford and
Bigger, 2002) or immunodeficient mice carrying engrafted
human liver cells (Mercer et al., 2001).
Hepatitis C virus (HCV) is an enveloped, positive-stranded
RNAvirus classified in the hepacivirus genus of the Flaviviridae
family (Lindenbach and Rice, 2001). The size of its genome is
approximately 10 kb comprising a large open reading frame
encoding a precursor polyprotein of approximately 3000 amino
acids. Cleavages of this polyprotein are co- and posttranslational
and generate at least 11 viral proteins, including a core protein,
two glycoproteins (GP), E1 and E2, and a number of non-
structural proteins (Penin et al., 2004). The transmembrane
domains (TMD) of the GPs contain heterodimerization and ER
retention sequences (Cocquerel et al., 1998, 1999, 2000), and
consistent with the intracellular localization of the GPs, HCV
is thought to assemble intracellularly, a common trait of the
Flaviviridae.
Cell attachment of flaviviruses generally leads to endocyto-
sis of bound virions (Fig. 1). Some of the cellular receptors
which mediate cell attachment and trafficking of this family of
viruses into endocytic vesicles of target cells are identified, and
glycosaminoglycans have been reported to play a role for entry
of several flaviviruses such as Dengue and Yellow Fever virus
(Chen et al., 1997; Germi et al., 2002; Tassaneetrithep et al.,
2003). A pH drop in the endocytosed vesicles then induces
conformational changes in the flaviviral GPs, which lead to
exposure of class II fusion peptides embedded in the respective
flaviviral GPs and ultimately to fusion between viral and
cellular membranes (Fig. 2). The objective of this review is to
summarize the contribution of different model systems to our
current knowledge about structure of the HCV GPs E1 and E2
and their roles in cell entry comprising cell attachment,
interactions with cellular receptors, endocytosis, and fusion.Fig. 1. Cartoon of pH-mediated viral entry into target cells. Interactions of the viru
subsequent pH drop within the endocytic particles then induces conformational chanPlasma-derived forms of native hepatitis C virus
HCV has been detected in many heterologous forms in the
blood of infected patients. Indeed, the virus is present either in its
‘free’ form or associated with high, low, or very low-density
lipoproteins or with immunoglobulins (Agnello et al., 1999;
Hijikata et al., 1993; Kanto et al., 1994; Manzini et al., 1998;
Monazahian et al., 2000; Pumeechockchai et al., 2002;
Thomssen et al., 1992). Indirect evidence suggests that the
lipoprotein-associated form is more ‘infectious’ (Hijikata et al.,
1993; Kanto et al., 1994) than the free form of the virus.
Furthermore, the virus has been described to circulate yet in
another form, as the so-called low-density lipo-viro-particle
(LVPs) in patients. These are nonenveloped nucleocapsids
that have immunoglobulin G Fc binding capacity. LVPs are
spherical particles enriched in triglycerides. At a minimum, they
contain apolipoprotein B, HCVRNA, and core protein (Andre et
al., 2002). The main source of LVPs is likely to be enterocytes
rather than hepatocytes, suggesting an interaction between
chylomicron and LVP assembly (Deforges et al., 2004).
So far, the investigation of HCV and its many different
lipoprotein- or immunoglobulin-associated forms has been
difficult because use of HCV sera ex vivo, e.g. for the infection
of primary hepatocytes or hepatoma cell lines, has proven
extremely difficult mainly for two reasons. The efficacy of the
virus to establish productive infection ex vivo is very low
(Fournier et al., 1998; Rumin et al., 1999). Furthermore, the
availability of HCV sera as well as primary hepatocytes is
significantly restricted. To overcome these limitations to the
study of HCV structure and cell entry, a significant number of
model systems have been developed which are described in the
sections below.
Hepatitis C virus like particles (HCV-LPs)
Structure definition requires virions. In the absence of HCV
virions, one common approach previously applied to many
other viruses has been to investigate HCV structure using in
vitro synthesized viral-like particles (V-LPs). V-LPs are defined
as self-assembling particles, which do not contain genomes and
thus cannot replicate. They are produced by introducing vectors
encoding, e.g. the HCV structural proteins core, E1, and E2,
into insect or mammalian cells. In transduced cells, the
formation of the HCV structural genes into V-LPs but with no
V-LP release into the cell supernatant has been described,s with cellular attachment factors lead to endocytosis of the viral particle. The
ges in the viral glycoproteins that lead to fusion of viral and cellular membranes.
Fig. 2. Cartoon of the full-length TBEV E protein in its different conformations. Organization of the TBEV E protein in different conformations: (A) On the mature
virus at neutral pH, the TBEV (tick-borne encephalitis virus) E protein lies on the viral membrane. The ectodomain of the protein consists of 3 domains (shaded in
gray) that form an elongated rod and associate into dimers in an anti-parallel fashion (see top view). Within this conformation, the fusion peptide loop (orange tip) is
buried in the dimer interface. As visible in the side view, the stem region (α-helices H1 and H2), which connects the ectodomain to the transmembrane domain, lies flat
on the viral membrane, interacting with the lipid heads of the outer leaflet of the lipid bilayer. The final two α-helices traverse the membrane and anchor the protein into
the membrane. (B) TBEV E in its final, postfusion conformation. Exposure to low pH leads to dissociation of the dimer, resulting in exposure of the fusion peptide
loops, whose interaction with cellular lipids converts the TBEV E dimer into a trimer. (C) The proposed structural fusion-intermediate. Helix H1 of the stem maintains
the ectodomain of TBEV E in an open conformation, allowing lateral interaction between adjacent trimers via the fusion peptide loops. This arrangement leads to the
formation of a ring of five trimers that destabilize the target membrane and leads to the formation of a fusion pore. For clarity, only two out of the five proposed trimers
that are proposed to form a fusion pore are drawn. Cartoon adapted from Bressanelli et al. (2004).
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blocked in these systems. Hepatitis C virus-like particles (HCV-
LPs) purified from cell lysates of insect cells have been shown
to exhibit morphological and biophysical properties similar to
those of virions isolated from HCV-infected patients (Barth et
al., 2003; Baumert et al., 1998, 1999; Clayton et al., 2002;
Lechmann et al., 2001; Triyatni et al., 2002a, 2002b; Wellnitz et
al., 2002; Xiang et al., 2002). Moreover, HCV-LPs have proven
highly useful for structural and functional studies of the core
protein of HCV (Blanchard et al., 2002, 2003; Roingeard et al.,
2004). HCV-LPs showed also antigenic properties similar to
those of wt HCV in binding and neutralization-of-binding
assays and are potential vaccine candidates (Baumert et al.,
1999; Lechmann et al., 2001; Qiao et al., 2003; Steinmann et al.,
2004). However, while they are useful in attachment assays, the
absence of a genomic marker in VLPs limits their use in entry
and infection assays.
Solubilized and chimeric HCV glycoproteins
In the absence of good model systems, biochemical
approaches towards the functional analysis of E1 and E2 have
been difficult due to the tendency of the HCV GPs to misfold
and aggregate and due to the strong ER retention and
heterodimerization sequences within their TMDs (Cocquerelet al., 2000; Dubuisson, 2000; Dubuisson et al., 2000).
Purification strategies for the HCV GPs required the use of
detergents to solubilize the proteins. The strong ER retention of
the HCV GPs made it very difficult to engineer cells which
express the GPs at their surface, an approach which has proven
valuable to study functions of many viral GPs in cell binding
and fusion. To circumvent these problems, several laboratories
produced solubilized forms of the GPs, where the TMDs had
been deleted. Soluble E2 (sE2) indeed was shown to bind
specifically to hepatocarcinoma but also other cell lines,
suggesting that the ectodomain of E2 mediates cell attachment
(Flint et al., 1999a, 1999b; Heo et al., 2004; Higginbottom et al.,
2000; Michalak et al., 1997; Petracca et al., 2000; Pileri et al.,
1998; Roccasecca et al., 2003; Scarselli et al., 2002; Triyatni et
al., 2002a, 2002b; Yagnik et al., 2000; Yamada et al., 2005).
Two potential HCV receptors, the human tetraspanin CD81 and
the human scavenger receptor SR-BI, were isolated in screens
based on sE2 binding (Pileri et al., 1998; Scarselli et al., 2002).
However, functional implementation of these receptor mole-
cules in HCV entry was confirmed only much later with the
development of the first infection assays for HCV. sE2 was also
tested to screen for antibodies potentially inhibiting the
attachment of HCV to target cells. Indeed, several antibodies
and sera, which inhibited binding of sE2 to target cells (NOB or
neutralization of binding assays), do neutralize HCV entry
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Owsianka et al., 2005). However, a comparison of sE2, purified
E1E2 complexes and HCV-LPs showed that some conforma-
tional discrepancy exists between these systems. Indeed, it
was shown that albeit comparable recognition of the three
different E2 ligands, a set of monoclonal antibodies, displayed
differential NOB activities in CD81 binding assays (Owsianka
et al., 2001). Furthermore, all these systems are limited to the
structural study of the GPs and their functions in cell attachment
and endocytosis. The first reported attempts to establish
infection assays for the HCV GPs aimed to incorporate the
HCV GPs onto heterologous viral cores. Because most viral
vector systems, which support incorporation of heterologous
GPs, assemble at the cell surface, the ER retention of the HCV
GPs rendered this approach difficult. HCV GPs were therefore
engineered to traffic to the cell surface by exchanging their
TMDs with those from heterologous, cell-surface targeted viral
GPs. Chimeric HCV GPs indeed relocalized and incorporated
efficiently onto heterologous viral core particles (Flint et al.,
1999a, 1999b; Lagging et al., 1998; Matsuura et al., 2001;
Meyer et al., 2000, 2004). Infectivity of resulting particles
has either been reported to be low (5-fold above background)
(Meyer et al., 2004) or absent (Buonocore et al., 2002),
presumably because in the absence of the HCV TMDs no
heterodimerization between E1 and E2 into functional com-
plexes occurred. Successful use of E1 and E2 TMD chimera
in the form of a fusion assay was so far reported by only one
group. It has previously been shown for several surface-
expressed viral glycoproteins that upon exposure to the
appropriate fusion trigger, i.e. low pH and/or a receptor, cells
expressing these viral GPs at their surface can fuse with target
cells expressing the appropriate viral receptor and form cell
syncytia. In line with this principle, Takikawa et al. (2000)
developed a cell–cell fusion assay using cell lines expressing E1
and E2 chimera at their surface in combination with a reporter
gene technique. Upon fusion of HCV GP chimera expressing
cells with target cells, a luciferase containing reporter construct
contained in the target cell population became activated. Fusion
was dependent on the presence of both chimeric E1 and E2 GPs
and occurred at a pH optimum of 5, suggesting pH-dependent
cell entry for HCV in analogy to other flaviviruses. Curiously,
the results were solely based on a read out of the luciferase
reporter; syncytium formation was not detected with this
system.
Hepatitis C virus pseudoparticles (HCVpp)
The description of the first surrogate HCV infection system
seemed paradox at first. It described the incorporation of
functional, unmodified HCV GPs on heterologous retro- and
lentiviral core particles (Bartosch et al., 2003b). It was unclear
how the intracellularly ER membrane-localized HCV GPs
incorporated on retroviral and lentiviral core proteins which
assemble and recruit viral GPs at the cell surface. This issue
resolved with two observations: upon overexpression of the
HCV GPs, a small population of the GPs leaves the ER and
traffics through endosomal compartments towards the cellsurface (Bartosch et al., 2003b; Drummer et al., 2003; Hsu et al.,
2003). In parallel studies on retroviral assembly, it was shown
that retro- and lentiviral capsid proteins do not necessarily
assemble at the cell surface, but that virions can form
intracellularly in endosomal compartments as well as at the
cell surface (Sherer et al., 2003). It has now been confirmed by
several laboratories that unmodified, full-length HCV GPs can
be recruited by retro- and lentiviral core proteins to form
infectious HCV pseudoparticles (HCVpp) (Bartosch et al.,
2003b; Drummer et al., 2003; Hsu et al., 2003; Sandrin et al.,
2005). These and other studies confirmed furthermore that the
presence of intact transmembrane domains of the GPs is
required for functionality of the resulting E1E2 complex
(Cocquerel et al., 2000; Dubuisson, 2000; Dubuisson et al.,
2000). HCVpp are produced by transfecting cells with
expression vectors encoding the full-length E1E2 polyprotein,
retroviral or lentiviral core proteins, and a packaging-competent
retro- or lentiviral genome carrying a marker gene. Transfected
cells secrete assembled viruses into the supernatant, which can
be harvested to infect naive target cells. Infection of target cells
can be monitored by assessing expression of the viral marker
gene. Production of HCVpp is relatively efficient, with an
average of 105 infectious units per ml supernatant (Bartosch et
al., 2003b) and can be performed at a convenient safety level.
HCVpp allow investigation of all functions mediated by the
HCV GPs and have been shown to closely mimic the entry and
serological properties of native and cell culture produced HCV
(Bartosch et al., 2003a, 2003b, 2003c; Bartosch and Cosset,
2004; Hsu et al., 2003; Lavillette et al., 2005a, 2005b;
Lindenbach et al., 2005; Logvinoff et al., 2004; McKeating et
al., 2004; Meunier et al., 2005; Wakita et al., 2005; Zhang et al.,
2004; Zhong et al., 2005).
Cell culture produced hepatitis C virus (HCVcc)
Recently, a full-length genotype 2a HCV genome, designat-
ed JFH-1 for Japanese fulminant hepatitis (Kato et al., 2001),
has been described that replicates without a requirement for cell
culture-adaptive mutations and produces virus particles that are
infectious in cell culture (Lindenbach et al., 2005; Wakita et al.,
2005; Zhong et al., 2005). This system, based on the
transfection of JFH-1 mRNA into highly permissive Huh7-
derived cell clones adapted to efficiently replicate HCV, is an
important milestone in HCV research and now allows the study
of the full viral life cycle in vitro. The first reports on cell
culture-produced HCV particles (HCVcc) have so far confirmed
previously established data on entry using other HCV model
systems and a common picture on viral entry is emerging. While
both glycoproteins are required for entry (Wakita et al., 2005),
cell lines of hepatic origin seem clearly to be among the most
permissive to HCVentry. There is also a consensus with respect
to the neutralizating activity of antibodies (Lindenbach et al.,
2005; Wakita et al., 2005; Zhong et al., 2005). However, while
HCVcc clearly are the system of preference for future analysis
of HCV biology, their use has its limitations in terms of safety,
the coupling of replication and infection, and the restriction to
just one genotype. Important tasks, which are currently
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structural and nonstructural sequences of all genotypes (Wakita
et al., 2005).
Functional and structural properties of the HCV
glycoproteins
In analogy to the known 3D structures of closely related
flaviviruses (dengue virus and tick-borne encephalitis (TBE)
virus) and alphaviruses (Semliki Forest (SF) virus) (Ferlenghi
et al., 2001; Kuhn et al., 2002; Lescar et al., 2001; Rey et al.,
1995), HCV is thought to adopt a classical icosahedral
scaffold, in which its two GPs are anchored into the viral
membrane via their TMDs. The functional unit of the HCV
GPs has been described as an E1E2 heterodimer (Dubuisson,
2000). Indeed, it has been shown by several groups that
HCVpp incorporate mainly noncovalently associated E1E2
heterodimers using nonreducing, denaturing gel electrophore-
sis and immunoprecipitation of HCVpp with conformation
sensitive antibodies (Flint et al., 2004; Op De Beeck et al.,
2004). Incorporated HCV GPs are heavily and heteroge-
neously glycosylated (Bartosch et al., 2003a, 2003b, 2003c;
Flint et al., 2004; Lozach et al., 2004; Op De Beeck et al.,
2004), and glycans within the E2 protein have been shown to
be vital for biogenesis as well as functionality of the GP
complex (Goffard et al., 2005). Co-expression of p7, a
putative viroporin, which is located immediately downstream
of E2 in the HCV polyprotein, and whose role in the viral life
cycle remains unclear, does not seemingly alter the expres-
sion, assembly, and functionality of the HCV GPs in the
context of HCVpp (Flint et al., 2004).
Besides their function as membrane anchors, the TMDs
serve as signal peptides and influence localization and
heterodimerization (Cocquerel et al., 2000; Michalak et al.,
1997). In contrast, the structures and roles of the ectodomains
remain rather unclear. The closest relative to HCV is the
flavivirus tick borne encephalitis virus (TBEV), whose GP
structure is well characterized (Bressanelli et al., 2004) (Fig. 2).
TBEV contains two GPs, prM and E, which initially form
heterodimers. prM serves as chaperone for E, and ‘maturation’
of prM by proteolytic cleavage of its ectodomain evokes
conformational changes that induce E into a dimeric arrange-
ment in which it is fusion-active and sensitive to low pH
exposure (Allison et al., 1995; Bressanelli et al., 2004; Stiasny
et al., 1996) (Fig. 2A). Within its ectodomain, E GP contains
both receptor interaction domains and a class 2 fusion peptide.
The ectodomain of E is linked to a TMD via a highly conserved
heptad repeat, called the stem region. After exposure to low pH,
this stem region plays a central role in the refolding of E
heterodimers into trimeric complexes, a process that induces the
merging of viral and target cell membranes (Allison et al., 1999;
Bressanelli et al., 2004) (Figs. 2B and C). As structure analysis
of the GPs of TBEV as well as dengue virus and SFV is well
advanced and because of their striking functional similarities to
the HCV GPs, these GPs are useful models for the analysis of
the HCV GPs. However, low sequence homologies even with
the closely related TBEV E protein render direct comparisonsdifficult. Indeed, the current models of the HCV GPs which
have been calculated as ‘best fit’ with respect to TBEV E
structure (Garry and Dash, 2003; Yagnik et al., 2000) still need
to be validated. The functional similarities between the HCV
GPs and other flavi or alphaviral GPs, which have been reported
to date, are manyfold. Like the case for other flaviviruses, it has
been shown that entry of HCVpp as well as HCVcc depends on
low pH with inhibitors of endosomal pH acidification such as
weak bases and vacuolar H(+)-ATPase inhibitors (Bartosch et
al., 2003a, 2003b, 2003c; Hsu et al., 2003; Koutsoudakis et al.,
personal communication). A number of functional studies,
mainly based on the use of sE2, suggest that E2 GP of HCV
mediates receptor binding. Mutational analysis of the putative
stem and transmembrane regions of HCV E2 indicates that
these regions play a role in refolding of the glycoproteins during
the fusion process (Drummer and Poumbourios, 2004). Also
consistent with flavivirus biology, low pH exposure of HCVpp
can cause conformational rearrangements and exposure of new
epitopes within E2 and partial dissociation of E1E2 complexes
(Keck et al., 2004; Op De Beeck et al., 2004). But in these
studies, it remains unclear whether the fusion peptide is
displayed by E1 or the E2 protein. Furthermore, unlike all
other members of the Flaviviridae, neither E1 nor E2 undergoes
any posttranslational cleavage during the assembly process,
which could be considered analogous to the prM maturation
cleavage of TBEV (Op De Beeck et al., 2004). Thus, it remains
to be elucidated how assembling HCVpp protect themselves
against premature fusion activation of their GPs.
HCV cell entry
HCV has so far only been shown to replicate in humans and
chimpanzees. Consistently, HCVpp harboring the GPs of all
major HCV genotypes as well as HCVcc display a marked
preference for human liver-derived cell lines (Bartosch et al.,
2003a, 2003b, 2003c; Lavillette et al., 2005a, 2005b;
Lindenbach et al., 2005; McKeating et al., 2004; Wakita et
al., 2005; Zhang et al., 2004; Zhong et al., 2005). Among the
most permissive human cells are Huh7, Hep3B, PLC/PRF5, and
primary human hepatocytes. Liver-derived cell lines from other
species like mice and rats, which are permissive to HCVpp
entry, have so far not been identified, and this is a setback for the
development of much needed animal models for HCV
(Bartosch et al., 2003a, 2003b, 2003c; Zhang et al., 2004).
Besides the liver, HCV has been repeatedly detected in patients
in extrahepatic compartments, including PBMCs and the brain
(Maggi et al., 1999; Morsica et al., 1999; Muller et al., 1993,
1994; Radkowski et al., 2002), but it is unclear whether the
virus can establish productive infections in these tissue
compartments in vivo. Whether this restriction is due to
inefficient entry or inefficient replication, or a combination of
both is unclear as well. However, studies with HCVpp,
performed by several laboratories, have shown that entry into
primary activated or unactivated PBMCs is not detectable
(Bartosch et al., 2003b; McKeating et al., 2004).
As the liver is the major organ known to replicate HCV, the
expression pattern of the cellular HCV receptor(s) has been
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this issue will only resolve with the identification of the HCV
receptor(s). Already a considerable number of receptors have
been proposed for HCV, and most of them have been isolated
based on binding studies with sE2 or HCV-LPs (see above).
Potential receptors include the low-density lipoprotein receptor
(Agnello et al., 1999; Monazahian et al., 1999), the human
tetraspanin CD81 (Pileri et al., 1998), the scavenger receptor BI
(Scarselli et al., 2002), the mannose binding lectins DC SIGN
and L SIGN (Gardner et al., 2003; Lozach et al., 2004; Lozach
et al., 2003; Pohlmann et al., 2003), the asialoglycoprotein
receptor (ASGPr) (Saunier et al., 2003), and glycosaminogly-
cans (Barth et al., 2003; Germi et al., 2002). Experimental data
using HCVpp have confirmed functional roles for CD81 and
SR-BI in HCV entry, and a requirement for CD81 in cell entry
has recently been confirmed with HCVcc (Lindenbach et al.,
2005; Wakita et al., 2005). Neither CD81 nor SR-BI has a liver-
specific expression profile. Curiously, these molecules are
expressed on a number of cell lines of hepatic and non-hepatic
origin. Because hepatic cell lines expressing CD81 and SR-BI
are permissive to HCVpp as well as HCVcc, while the non-
hepatic cell lines expressing CD81 and SR-BI are not or only to
very low levels, it is tempting to speculate that the missing entry
factors for HCVare indeed liver-specific molecules (Bartosch et
al., 2003a, 2003b, 2003c; Lindenbach et al., 2005; Zhang et al.,
2004).
Lectins
Classical C-type lectins have various roles and can act both
as adhesion and as pathogen recognition receptors. They
contain carbohydrate recognition domains (CRDs) which bind
carbohydrate structures in a calcium-dependent manner. Among
the membrane resident forms of C-type lectins are DC-SIGN
(dendritic cell-specific intercellular adhesion molecule-3-grab-
bing nonintegrin) and L-SIGN (DC-SIGNr, liver, and lymph
node specific). As adhesion receptor DC-SIGN mediates the
contact between dendritic cells and T lymphocytes and the
rolling of DCs on endothelium. L-SIGN, expressed on cells
forming the epithelium of liver sinusoids (LSEC), which are
specialized capillary vessels characterized by the presence of
resident macrophages which adhere to L-SIGN, mediates
LSEC–leukocyte interactions. As pathogen uptake receptors,
the main function of C-type lectins is to bind and subsequently
internalize for subsequent elimination a variety of microorgan-
isms including viruses, bacteria, fungi, and some parasites
(Cambi et al., 2005). However, some viruses have been shown
to escape degradation and exploit C-type lectins as entry and
also as attachment factors. DC-SIGN, as well as L-SIGN,
expressed on permissive, receptor-expressing cells have been
shown to bind virus with high affinity and increase its
infectivity. Alternatively, when present on cells devoid of the
viral receptor, they can transmit virus to close-by receptor-
positive cells. L-SIGN and DC-SIGN have therefore been also
termed ‘capture’ receptors and have been shown to specifically
bind the HCV GPs presented in soluble, chimeric, and native
forms and to transmit them to neighboring permissive cells.Particle transmission and uptake can be blocked by mannan and
antibodies recognizing the CRD of SIGN receptors (Cormier et
al., 2004a, 2004b; Gardner et al., 2003; Lozach et al., 2004;
Lozach et al., 2003; Ludwig et al., 2004; Pohlmann et al., 2003).
While DC- and L-SIGN do not render nonpermissive cells
permissive to HCV, their respective expression patterns on
dendritic cells and LSEC suggest that they may contribute in
vivo to the capture and delivery of HCV to the liver.
Another lectin that has been implicated into HCV entry, and
that is expressed in liver parenchymal cells, is the asialoglyco-
protein receptor (ASGPr). It interacts and mediates endocytosis
of a wide variety of desialylated glycoproteins that contain
terminal galactose or N-acetylgalactosamine residues (Stockert,
1995). Among the uptake of glycoproteins from the plasma,
other functions of ASGPr include the clearance of fibronectin,
IgA, and plasma lipoproteins. Using HCV-LPs in NOB assays
on primary human hepatocytes and other cell lines, ASGPr-
specific ligands were shown to inhibit binding and endocytosis
of HCV-LPs into target cells. Furthermore, binding and
internalization of HCV-LPs into mouse 3T3-L1 cells were
only observed upon overexpression of human ASGPr, suggest-
ing that this receptor may play a role in HCV cell entry (Saunier
et al., 2003).
Glycosaminoglycans
Glycosaminoglycans (GAGs) are used by many different
viruses to bind to target cells. In particular, heparan sulfate (HS)
may allow viruses to adhere to target cells before high affinity
receptors induce specific adhesion and entry. Dengue virus type
2 and Yellow fever virus, both Flaviviridae, use GAGs even as
cellular receptors (Chen et al., 1997; Germi et al., 2002). For
HCV, it has been shown that polyanionic compounds such as
heparin, dextran sulfate, and suramine can inhibit binding of
wild-type HCV or pseudoparticles displaying chimeric E1 and
E2 GPs to target cells (Cribier et al., 1998; Garson et al., 1999;
Germi et al., 2002; Meyer et al., 2000), suggesting that GAGs
and in particular heparin like GAGs may be involved in HCV
cell attachment.
LDL receptor
The low-density lipoprotein receptor (LDLr) transports
cholesterol-containing lipoprotein particles from the extracel-
lular medium into cells. The most important physiological
ligand for the LDLr is low-density lipoprotein (LDL), which
contains a single copy of the apolipoprotein B-100 as its pri-
mary protein component. In addition, the receptor also exhibits
high-affinity binding of lipoproteins that contain multiple
copies of apolipoprotein E, like some forms of very low-
density lipoprotein (vLDL) and certain intermediate density
lipoproteins. Receptor ligand complexes enter cells by endocy-
tosis via clathrin-coated pits and are delivered to endosomes,
where low pH triggers release of bound lipoprotein particles.
Released lipoprotein particles proceed to lysosomes, where the
cholesterol esters are hydrolyzed to free cholesterol (Beglova
and Blacklow, 2005).
7B. Bartosch, F.-L. Cosset / Virology 348 (2006) 1–12An involvement of LDLr in HCV entry originated with the
observation that HCV infection is associated with mixed
cryoglobulinemia. Indeed, vLDL is selectively associated with
HCV in type II cryoglobulin complexes. Furthermore, HCV
virions were detected in keratinocytes present within the
vasculitic lesions caused by the cryoglobulin complexes, but
not in normal skin of the same patients. And finally, levels of
LDLr were upregulated on keratinocytes in cutaneous vasculitis
lesions compared with normal skin. These observations and the
finding that anti-betalipoprotein precipitates HCV from infected
serum suggested that LDLr may be a receptor for HCV
complexed to vLDL or LDL (Agnello and Abel, 1997; Agnello
et al., 1999; Thomssen et al., 1992). Indeed, it has been shown
that endocytosis of HCV correlates with the presence of LDLr
and its activity by performing receptor competition assays with
anti LDLr antibodies, with anti-apolipoprotein B and E
antibodies as well as with vLDL and LDL (Agnello et al.,
1999; Bartosch et al., 2003b; Germi et al., 2002; Monazahian et
al., 1999; Wunschmann et al., 2000). That LDLr is not the
exclusive means of cell entry of HCV suggests the fact that it is
expressed on cell lines which are not permissive to HCVpp
(Bartosch et al., 2003c), still its potential role in the uptake of
lipoprotein associated HCV is highly interesting and needs to be
followed up.
CD81—a tetraspanin
CD81 is a member of the tetraspanin superfamily and very
ubiquitously expressed. Key feature of tetraspanins is the
formation of an extended network at the cell surface, which
organizes the membrane, by homologous, autologous, and hete-
rologous protein interactions. Such ‘tetraspanin-enriched micro-
domains’ (TEMs) are emerging as entities physically and
functionally distinct from lipid rafts and have very distinct
roles including cellular signaling, migration, adhesion, fusion,
cytosceletal reorganization, and proliferation. Tetraspanins have
no intrinsic enzymatic activity or typical signaling motifs, with
the exception of the recently reported 14–3–3 binding motif in
the C-terminus of CD81 (Clark et al., 2004). It is therefore
thought that they act primarily as adapter proteins, mediating and
modulating interactions of associated proteins in TEMs. More
specifically, CD81 has been shown to be part of the B/T cell
receptor complex, and is enriched in exosomes, suggesting that it
may be involved in regulating vesicle fusion or fission (Hemler,
2003).
CD81 possesses short intracellular N- and C-termini, four
transmembrane domains, and a small and a large extracellular
loop (SEL and LEL). The LEL is sufficient to bind sE2
(Petracca et al., 2000; Pileri et al., 1998) and elucidation of its
crystal structure revealed a composition of five α-helices
comprising a stalk and head domain. The head domain is
stabilized by two disulfide bonds, which are required for the
interaction with sE2 (Drummer et al., 2005). CD81 was
demonstrated to be essential for HCV glycoprotein-mediated
entry through the use of HCVpp of all genotypes: infection of
primary human hepatocytes or hepatoma cell lines was inhibited
by anti-CD81 antibodies (Bartosch et al., 2003c; Cormier et al.,2004a, 2004b; Hsu et al., 2003; Lavillette et al., 2005a, 2005b;
McKeating et al., 2004) and after downregulation of CD81
using an siRNA approach (Zhang et al., 2004). HepG2 and
HH29 cells, hepatoma cell lines, which do not express
endogenously CD81, become permissive to HCVpp of all
genotypes upon ectopic CD81 expression (Bartosch et al.,
2003c; Lavillette et al., 2005a, 2005b; McKeating et al., 2004;
Zhang et al., 2004). These data were confirmed very recently
with HCVcc (Lindenbach et al., 2005; Wakita et al., 2005).
Interestingly, chimera between CD81 and its close relative CD9,
which were expressed in HepG2 cells and used to demonstrate
that the LEL of CD81 is sufficient to mediate entry into HepG2
cells, gave different results when tested for binding to sE2.
Binding of sE2 was sensitive to single point mutations within
the LEL, as previously described (Flint et al., 1999a, 1999b;
Higginbottom et al., 2000). However, HCVpp entry was not
affected by these mutations (Zhang et al., 2004), confirming that
structural and/or functional differences exist not only between
sE2 and HCV-LPs but also HCVpp.
Overexpression of CD81 renders the hepatoma cell line
HepG2 permissive to HCVpp. However, introduction of CD81
into cell lines of other species, including NIH 3T3 or CHO cells,
did not have the same effect (Bartosch et al., 2003c). Those cells
remained nonpermissive suggesting that CD81 is required, but
by itself not sufficient to mediate cell entry. Whether CD81 is
involved in cell attachment, endocytosis, fusion, or another step
remains unclear as well. However, Cormier et al. (2004a,
2004b), who performed receptor competition studies with anti-
CD81 antibodies, showed that the sensitivity of unbound versus
cell-bound HCVpp to the antibody was similar, suggesting that
CD81 acts after attachment of virions to the cell surface. While
CD81 may introduce conformational changes or influence
HCVpp entry in an indirect fashion, it is not an obvious
candidate to mediate endocytosis of the virus, as it is not
strongly recycled from the surface into the cell's interior in
contrast to SR-BI (Silver et al., 2001), another molecule shown
to be involved in HCVpp entry.
The human scavenger receptor class B type I (SR-BI)
SR-BI is a 509-amino acid glycoprotein with two C- and N-
terminal cytoplasmic domains separated by a large extracellular
domain involved in the cellular lipometabolism. Besides its
association with apoptosis, SR-BI serves as lipoprotein receptor
responsible for selective uptake of cholesteryl ester from high-
density lipoprotein (HDL), via a two-step mechanism involving
the binding of lipoproteins to its extracellular domain followed
by lipid uptake (Connelly and Williams, 2003). Similarly to
CD81, SR-BI was identified as a receptor mediating sE2
binding to human hepatic cells (Scarselli et al., 2002).
Interactions between sE2 and SR-BI were found to be selective
since neither mouse SR-BI nor the closely related human
scavenger receptor CD36 was able to bind sE2. SR-BI
recognition by sE2 required the hyper variable region of E2
(HVR1) and could be competed out with a polyclonal serum
against SR-BI (Barth et al., 2005; Bartosch et al., 2003c;
Scarselli et al., 2002), but not with a truncated, soluble form of
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confirmed with HCVpp in receptor competition assays using
polyclonal anti-SR-BI serum. Similar to its neutralizing activity
in sE2 binding assays, this serum inhibited HCVpp entry
efficiently and specifically in a dose-dependent fashion
(Bartosch et al., 2003c). In Huh7 cells, in which SR-BI
expression was downregulated to less than 5% of endogenous
levels using an siRNA approach, entry of HCVpp was reduced
by 90% (Lavillette et al., 2005a, 2005b). This applied, albeit
with some variation, to all major HCV genotypes. How SR-BI
mediates HCV entry requires further investigation. But it has
become clear that the HVR1 domain is a critical region required
for the functional interaction between E2 and SR-BI. Indeed,
deletion of this region decreases sE2 binding to SR-BI (Scarselli
et al., 2002). HCVpp displaying an HVR1 deletion display a
decrease in infectivity by over 10-fold and loose sensitivity to
inhibition by the polyclonal anti-SR-BI serum (Bartosch et al.,
2003c). While these data clearly implement SR-BI into HCV
entry, it is currently not possible to say whether SR-BI simply
modulates HCVpp entry or whether it is, like CD81, an essential
entry factor. Indeed, correlations between permissiveness to
HCVpp entry and expression levels of CD81 and SR-BI showed
that all permissive cell lines identified so far are of hepatic
origin and express both receptors, albeit to variable levels. In
contrast, multiple cell lines of non-hepatic origin express both
SR-BI and CD81, yet fail to support HCVpp entry (Bartosch et
al., 2003a, 2003b, 2003c; Zhang et al., 2004). Finally, cell lines
of nonhuman origin, like e.g. CHO cells, engineered to express
human CD81 and SR-BI, do not become permissive, indicating
that additional factor(s), probably of hepatic origin, are required
for HCV entry. Thus, in the absence of a cell line of hepatic
origin, which does not endogenously express SR-BI and which
would allow ectopic introduction of SR-BI, it is difficult to
differentiate between a requirement for SR-BI in HCVpp entry
versus a modulation of HCVpp entry by SR-BI. That SR-BI
modulates HCV entry has recently been confirmed by reports
which demonstrated that serum factors, and specifically a ligand
to SR-BI, high-density lipoprotein (HDL), can enhance the
infectivity of HCVpp (Bartosch et al., 2005; Lavillette et al.,
2005a, 2005b; Meunier et al., 2005; Voisset et al., 2005).
High-density lipoprotein
HDL-mediated enhancement of HCVpp infection consti-
tutes a novel mechanism of viral entry. While enhancement
of infection by antibodies and/or complement has previously
been reported for several viruses including HIV (Fust, 1997),
Dengue (Halstead, 2003), and Ebola viruses (Takada et al.,
2003), HCVpp infection enhancement is resistant to deacti-
vation of complement and occurs independently of
immunoglobulins.
HDL-mediated infection enhancement can increase infectiv-
ity of HCVpp by over 10-fold (Bartosch et al., 2005) and clearly
involves SR-BI (Bartosch et al., 2005; Voisset et al., 2005) and
conserved residues within the HVR1 of the E2 GP (Bartosch et
al., 2005). Indeed, HDL-mediated enhancement of HCVpp
infection is sensitive to downregulation of SR-BI (Bartosch etal., 2005; Voisset et al., 2005), and can be specifically inhibited
by anti-SR-BI antibodies (Bartosch et al., 2005) and by drugs
which target SR-BI to inhibit cholesterol uptake from HDL
(Bartosch et al., 2005; Voisset et al., 2005). HDL stimulation of
HCVpp entry still requires CD81, as HepG2 cells do not
become permissive to HCVpp in the presence of HDL
(Bartosch et al., 2005). Furthermore, the effect is restricted to
HDL of human and old world primates, HDL of other species
does not have a stimulatory effect (Bartosch et al., 2005;
Meunier et al., 2005). The mechanism by which HDL enhances
HCVpp infectivity is unclear at the moment. But it has been
proposed that the enhancing component is ApoCI, an apo-
lipoprotein located on the surface of HDL particles. Recombi-
nant ApoCI enhances HCVpp entry as efficiently as HDL and
HDL-induced enhancement of HCVpp infectivity is sensitive to
anti-ApoCI antibodies (Meunier et al., 2005). Furthermore,
HDL can enhance the infectivity of HCVpp which are already
bound to target cells (Bartosch et al., 2005; Voisset et al., 2005),
but whether HDL/ApoCI needs to physically interact with
HCVpp and/or SR-BI to stimulate infection remains unclear. So
far, no protein/protein or lipid/protein interactions between
HDL and HCVpp have been demonstrated (Bartosch et al.,
2005; Voisset et al., 2005). These negative results could imply
that HDL acts on HCV entry indirectly by stimulating the
physiological activity of SR-BI or that interactions between
HDL and HCVpp are transient and/or of low affinity, just like
interactions between HDL and SR-BI are of a transient nature
due to loss of affinity to SR-BI after cholesteryl uptake (Liu and
Krieger, 2002).
Besides enhancement of infection, the presence of HDL has
also been shown to protect HCVpp from neutralizing antibodies
(Bartosch et al., 2005), and this makes the involvement of
HVR1 in entry enhancement significant. The genetic variability
of HVR1 has been suggested to help the virus adapt to its host
and thus correlate with persistent infection (Farci et al., 2000).
That implies that HVR1 may play three different roles in HCV
biology: enhancement of cell entry, protection of virions from
(cross)-neutralizing antibodies, and mutational immune escape.
Preserving the three functions of HVR1 may be essential for
viral persistence and requires that the virus compromises
between a high degree of genetic variability in the HVR1 and
conserving HVR1 residues implied in HDL-mediated infection
enhancement. However, the role and influence HDL as well as
other lipoproteins in vivo, in the lifecycle of native HCV, need
to be confirmed.
Conclusion
A significant number of cellular factors have so far been
implicated in HCVentry. While glycosaminoglycans and lectins
are likely to facilitate initial cell attachment and possibly
endocytosis, they are unlikely to present high affinity binding
receptors which are capable of inducing conformational changes
in the GPs that are required to induce the fusion process. LDLr as
well as ASGPr have both been shown to mediate endocytic
uptake of HCV into target cells, but whether this effect is due to
direct binding of HCV to these molecules or rather mediated by
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the case of LDLr. Future investigation of the roles of these
molecules in endocytosis will clarify this issue.
Once within an endocytic vesicle, HCV requires exposure to
low pH in order to fuse with the cellular target membrane. But
how and at what stages of its entry HCV needs to bind to
cellular receptors with high affinity in order to convert into a
fusogenic conformation remain unclear. Both CD81 and SR-BI
have been shown to interact directly with HCVand are therefore
potential high-affinity receptor candidates. While HCV entry
clearly requires the presence of CD81 in a target cell, SR-BI has
been shown to be involved using receptor competition assays.
But it remains unclear whether HCV entry really requires the
presence of SR-BI or is rather modulated by this factor. With the
establishment of full HCV infection systems, the long awaited
identification of the cellular factor which mediates HCV entry
alongside CD81 and possibly other entry factors has become
possible.
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